If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
On May 29, 2020, the FDA approved ramucirumab, in combination with erlotinib, for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.1
Enclosed Prescribing Information
EGFR = epidermal growth factor receptor
FDA = Food and Drug Administration
NSCLC = non-small cell lung cancer
Date of Last Review: May 29, 2020